<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5761-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOLVADEX 10 MG TABs
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAMOXIFEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Nolvadex is<br />The name of your medicine is Nolvadex. Nolvadex contains a medicine called tamoxifen,which belongs to a group of medicines called &lsquo;anti-oestrogens&rsquo;.</p><p dir="ltr">What Nolvadex is used for<br />&bull; Nolvadex is used to treat breast cancer.<br />&bull; Nolvadex can also be used to treat infertility in women caused by a failure to produce and<br />release eggs (ovulate) properly.<br />&bull; Nolvadex can also reduce the risk of developing breast cancer occurring in those women who have an increased likelihood of developing breast cancer (your risk). It is important that your healthcare professional calculates your risk of developing breast cancer and discusses the result with you before commencing treatment. There are a number of specific tools available to calculate breast cancer risk, based on information such as your age, family history, genetics, reproductive factors (e.g. age when periods started and stopped, had children or not, taken or taking hormonal replacement therapy and/or oral contraceptive pill) and history of breast disease. Although the tools can estimate your risk, it doesn&rsquo;t mean you will get breast cancer, being at increased risk means you have a higher chance of developing breast cancer. If you and your healthcare professional are considering using Nolvadex for this, it is important to understand the benefits as well as the side effects of taking Nolvadex because you don&#39;t currently have breast cancer and Nolvadex reduces, but does not stop the risk of developing breast cancer.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you want to know more about how to decide whether tamoxifen is right for you, there is more information for patients on the National Institute for Health and Care Excellence website. Ask your doctor to talk to you about the information which is available for patients.</p><p dir="ltr">How Nolvadex works<br />Oestrogen is a natural substance in your body known as a &lsquo;sex hormone&rsquo;. Some breast cancers need oestrogen to grow and Nolvadex works by blocking the effects of oestrogen.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not take Nolvadex:<br />&bull; If you are pregnant or think you might be pregnant (see the section on &lsquo;Pregnancy&rsquo;below).<br />&bull; If you are allergic to tamoxifen or any of the other ingredients of this medicine (listedin section 6).<br />&bull; If you are taking anastrozole.<br />&bull; If you are taking any treatment for infertility.<br />&bull; If you have had blood clots in the past and the doctor did not know what caused them.<br />&bull; If someone in your family has had blood clots with the cause not known.<br />&bull; If your doctor has told you that you have an illness which runs in the family that<br />increases the risk of blood clots.<br />&bull; If you are taking medicines used to prevent blood clots such as warfarin Do not take Nolvadex if any of the above apply to you. If you are not sure, talk to your doctor<br />or pharmacist before taking Nolvadex.</p><p dir="ltr">Warnings and precautions</p><p dir="ltr"><br />Talk to your doctor or pharmacist before taking Nolvadex.<br />In delayed breast reconstruction operation (weeks to years after the primary breast operation when your own tissue is moved to shape a new breast), Nolvadex may increase the risk of the<br />formation of blood clots in the small vessels of the tissue flap which may lead to complications.</p><p dir="ltr"><br />Nolvadex therapy may be used to reduce the risk of breast cancer and it can be associated with serious side effects such as blood clots in the veins of your leg (deep vein thrombosis),<br />blood clots in your lungs (pulmonary embolus) and uterine cancer, all of which can be fatal. Other less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities<br />and pelvis pain may also occur.</p><p dir="ltr">Whether the benefits of treatment outweigh the risks depends on your age, health history, your level of breast cancer risk and on your personal judgement. Nolvadex therapy to reduce the risk of breast cancer may not be appropriate for all women at increased risk.</p><p dir="ltr">All assessments with your healthcare professional of the potential benefits and risks prior to starting therapy are essential. You should understand that Nolvadex reduces, but does not eliminate the risk of breast cancer.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have a history of hereditary angioedema as Nolvadex may cause or worsen symptoms of hereditary angioedema. If you experience symptoms such as swelling of the face, lips,<br />tongue and/or throat with difficulty in swallowing or breathing, contact a doctor immediately.</p><p dir="ltr">Serious skin reactions<br />Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with Nolvadex treatment. Stop using Nolvadex and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p dir="ltr">Children<br />This medicine is not for use in children.</p><p dir="ltr">Operations<br />If you are to undergo planned surgery, you should tell your doctor or pharmacist as they may wish to consider stopping your treatment for a short period.</p><p dir="ltr">Other medicines and Nolvadex<br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Nolvadex can affect the way some other medicines work and some medicines can have an effect on Nolvadex.</p><p dir="ltr">In particular, tell your doctor or pharmacist if you are taking any other medicines:<br />&bull; Oral contraceptives<br />&bull; Hormone replacement therapy (HRT)<br />&bull; Antidepressants (e.g. paroxetine, fluoxetine).<br />&bull; Bupropion (used as an antidepressant or aid to smoking cessation).<br />&bull; Quinidine (for example used in the treatment of cardiac arrhythmia).<br />&bull; Cincalet/cinacalcet (for treatment of disorders of the parathyroid gland).<br />&bull; Blood thinning medicines such as warfarin. These are known as &lsquo;anti-coagulants&rsquo;<br />&bull; Rifampicin which is used for tuberculosis (TB).<br />&bull; Medicines known as &lsquo;aromatase inhibitors&rsquo; that are used to treat breast cancer. These include anastrozole, letrozole and exemestane.</p><p dir="ltr">Contraception<br />Women who can become pregnant should use adequate non-hormonal contraception (e.g., barrier contraception) during treatment with Nolvadex and for an additional nine months after stopping treatment.</p><p dir="ltr">Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p dir="ltr">Pregnancy</p><ul dir="ltr"><li>Do not take Nolvadex if you are pregnant. This is because it may affect your unborn baby.</li><li>Avoid becoming pregnant and breast feeding whilst taking Nolvadex and for nine months after stopping treatment.</li><li>As you should not become pregnant when taking Nolvadex, please see your doctor for advice on what contraceptive precautions you should take, as some may be affected by Nolvadex.</li><li>You should see your doctor immediately if you think you may have become pregnant after starting to take Nolvadex.</li></ul><p dir="ltr">Breast-feeding<br />Talk to your doctor before taking Nolvadex if you are breast-feeding.</p><p dir="ltr">Driving and using machines<br />Nolvadex is not likely to affect your ability to drive or use any tools or machines. However, tiredness has been reported with the use of Nolvadex and caution should be observed when driving or operating machinery while such symptoms persist.</p><p dir="ltr">Nolvadex tablets contain lactose, titanium dioxide and sodium<br />&bull; Nolvadex tablets contain lactose, which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.<br />&bull; Nolvadex tablets contain titanium dioxide. This may cause a problem in a small number of people who are sensitive to this ingredient.<br />&bull; This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take Nolvadex exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />&bull; NOLVADEX treatment must be initiated and monitored under the supervision of a physician experienced in oncology.<br />&bull; NOLVADEX is a hazardous drug. Need caution when handling NOLVADEX to minimize risk of exposure.<br />&bull; Personal not taking NOLVADEX should not exposed to it.<br />&bull; Tablets should be swallowed whole.<br />&bull; The tablets should not be broken or crushed.</p><p dir="ltr">Breast cancer treatment<br />The recommended dose for breast cancer is 20 mg daily.</p><p dir="ltr">Infertility<br />The dose for infertility depends on your periods (menstrual cycle).<br />&bull; If you are having regular periods, the recommended dose is one 20 mg tablet daily on the 2nd, 3rd, 4th and 5th days of your period.<br />&bull; If this does not work, your doctor may suggest that you take a higher dose of Nolvadex<br />during your next period. If this happens, the usual dose is 40 mg or 80 mg daily on the 2nd, 3rd, 4th and 5th days of your period.<br />&bull; If you are not having regular periods, you can start taking the tablets on any day of the month.</p><p dir="ltr">Reducing the risk of breast cancer<br />The recommended dose for reducing the risk of breast cancer is 20 mg daily for 5 years.Your healthcare professional will calculate your risk of breast cancer occurring using<br />information about you, your medical history and any family history of breast cancer.</p><p dir="ltr">If you take more Nolvadex than you should, talk to a doctor or pharmacist straight away.<br />If you forget to take Nolvadex<br />&bull; If you forget to take a dose, take it as soon as you remember. However, if it is nearly<br />time for the next dose skip the missed dose.<br />&bull; Do not take a double dose (two doses at the same time) to make up for a forgotten<br />dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Nolvadex D can cause side effects, although not everybody gets them.</p><p dir="ltr"><strong>Stop taking Nolvadex D and tell your doctor straight away if you notice any of the following side effects &ndash; you may need urgent medical treatment:</strong></p><p dir="ltr">&nbsp;</p><ul dir="ltr"><li>Symptoms of a blood clot. These include swelling of the calf or leg, chest pain, being short of breath or suddenly feeling weak.</li><li>Sudden onset of weakness or paralysis of the arms or legs, sudden difficulty with speaking, walking, difficulty in holding things or difficulty in thinking, any of which may occur because the blood supply in the blood vessels of the brain is reduced. These symptoms could be signs of a stroke.</li><li>Difficulty in breathing.</li><li>Swelling of the face, lips, tongue or throat which may make it difficult to swallow.</li><li>Swelling of the hands, feet or ankles.</li><li>Nettle rash (also called &lsquo;hives&rsquo; or &lsquo;urticaria&rsquo;).</li><li>Reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms [Stevens-Johnson</li><li>syndrome, toxic epidermal necrolysis] &ndash; these side effects occur rarely.</li><li>Swelling of the face, lips, tongue or throat, difficulty in swallowing or breathing (angioedema). Nolvadex may cause or worsen symptoms of hereditary angioedema.</li></ul><p dir="ltr"><strong>Tell your doctor straight away if you notice any of the following:</strong><br />&bull; Unusual bleeding from your vagina.<br />&bull; Irregular periods.</p><p dir="ltr">&bull; Vaginal discharge.<br />&bull; A feeling of discomfort in the lower tummy (pelvis) such as pain or pressure. These effects may mean that there have been changes to the lining of your womb (the endometrium). Sometimes these effects are serious and could include cancer. They can happen during or after treatment with Nolvadex.</p><p dir="ltr">Other possible side effects:<br />Very common (may affect more than 1 in 10 people)<br />&bull; Nausea.<br />&bull; Fluid retention.<br />&bull; Skin rash.<br />&bull; Hot flushes.<br />&bull; Tiredness.<br />&bull; Depression<br />Common (may affect up to 1 in 10 people)<br />&bull; Anaemia (a blood problem which means you have too few red blood cells).<br />&bull; Changes in vision due to cataracts or changes to the retina of your eye.<br />&bull; Increased amounts of fats in your blood (shown by blood tests).<br />&bull; Allergic reactions.<br />&bull; Leg cramp.<br />&bull; Changes in the womb (including changes to its lining and benign growths).<br />&bull; Headache.<br />&bull; Feeling light-headed.<br />&bull; Itching of the genitals.<br />&bull; Thinning of the hair.<br />&bull; Vomiting.<br />&bull; Diarrhoea.<br />&bull; Constipation.<br />&bull; Changes in blood tests of liver function.<br />&bull; Formation of fatty liver cells.<br />&bull; Muscle pain.<br />&bull; Sensory changes (including taste disorder and numbness or tingling in the skin).<br />&bull; Increased risk of blood clots (including clots in small vessels).<br />Uncommon (may affect up to 1 in 100 people)<br />&bull; Blood problems. This can make you bruise more easily, get serious infections, or feel<br />very tired or breathless.<br />&bull; Changes to your vision and difficulty seeing.<br />&bull; Swelling of the pancreas. This may cause moderate to severe pain in the stomach.<br />&bull; Changes in the amount of calcium in your blood. The signs may include feeling very sick, being sick a lot or being thirsty. Tell your doctor if this happens because he or she may want you to have blood tests.</p><p dir="ltr">&bull; Inflammation of the lungs. The symptoms may be like pneumonia (such as feeling short of breath and coughing).<br />&bull; Liver cirrhosis (problems with your liver).</p><p dir="ltr">Rare (may affect up to 1 in 1,000 people)<br />&bull; Severe blood problems. This can make you bruise more easily, get serious infections,<br />or feel very tired or breathless.<br />&bull; Changes to the cornea of your eye.<br />&bull; Problems with the nerve that connects your retina to your brain.<br />&bull; Swelling of the optic nerve.<br />&bull; On occasions more severe liver diseases have occurred from which some patients have<br />died. These liver diseases include inflammation of the liver, liver cirrhosis, liver cell<br />damage, reduced bile formation, and failure of the liver. Symptoms may include a<br />general feeling of being unwell, with or without jaundice (yellowing of the skin and<br />eyes).<br />&bull; Damage to blood vessels causing red or purple dots in the skin.<br />&bull; Severe skin disorder. The symptoms include redness, blistering and peeling.<br />&bull; Cells normally only found in the lining of the womb found elsewhere in your body,<br />cysts on the ovaries, and cancer (the signs of this are given above).<br />&bull; Non-cancerous mass in the inner lining of the vagina (called vaginal polyp).<br />&bull; At the beginning of treatment, a worsening of the symptoms of your breast cancer<br />such as an increase in pain and/or an increase in the size of the affected tissue may<br />occur (known as tumour flare).<br />Very rare (may affect up to 1 in 10,000 people)<br />&bull; Inflammation of the skin characterized by rash or erythema, very often on areas<br />exposed to light (a condition called cutaneous lupus erythematosus).<br />&bull; A skin condition characterised by skin blisters in areas exposed to the light, this is due<br />to the increased liver production of a special group of cell pigments (called<br />porphyrins).<br />&bull; Radiation recall - skin rash involving redness, swelling, and/or blistering (like severe<br />sunburn) of the skin after receiving radiation therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">NOLVADEX is a hazardous drug, need caution when handling to minimize risk of exposure.<br />&bull; The tablets should not be divided, broken or crushed.<br />&bull; Transport and store medicine in the original container or blister.<br />&bull; For medication administration, use gloves and wash hands thoroughly before and<br />after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup.<br />&bull; People who are not taking patient should not be exposed to it.<br />&bull; Caution should be observed in handling broken or crushed tablets Avoid direct contact of the NOLVADEX with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.<br />&bull; Pregnant should avoid exposure to NOLVADEX tablets.<br />&bull; Family members use gloves when handling laundry or cleaning within or around toilets.<br />&bull; Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy. If available, use separate bathroom from family members.<br />&bull; Conduct double washing of linens and wash them separately from other family laundry.<br />&bull; If your doctor tells you to stop taking the meditation, or expired. Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine<br />you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines.<br />&bull; These measures will help protect environment.</p><p dir="ltr">Only keep the medicine if your doctor tells you to.<br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.<br />&bull; Do not store above 30oC. Store your tablets in the original package. Keep the blister strip in the carton. This will protect your medicine from light and moisture.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is tamoxifen.<br />Each Nolvadex 10 mg tablet contains Tamoxifen Citrate Ph. Eur. 15.2 mg equivalent to 10 mg tamoxifen.<br />Each Nolvadex D 20 mg tablet contains Tamoxifen Citrate Ph. Eur. 30.4 mg equivalent to 20 mg Tamoxifen.<br />The other ingredients are croscarmellose sodium, gelatin, lactose, macrogol, magnesium stearate, maize starch, methylhydroxypropylcellulose and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nolvadex 10 mg Tablets are white to off-white, round, biconvex, film-coated tablets, with
markings on one face and plain on the reverse. They come in packs (blister strips or bottles) of
30 or 250 tablets.
Nolvadex D 20 mg tablets are octagonal, white film-coated tablets. They are marked
Nolvadex D on one side. They come in packs of 30 or 250 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The Marketing Authorisation for Nolvadex D is held by</p><p dir="ltr">AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom.</p><p dir="ltr"><br />Manufacturer:<br />AstraZeneca UK Ltd, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, United Kingdom.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما دواء نولفادكس </strong></p><p dir="RTL">اسم الدواء نولفادكس. يحتوي نولفادكس على دواء يُسمى تاموكسيفين، والذي ينتمي إلى مجموعة من الأدوية تُسمى &quot;مضادات الاستروجين&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال نولفادكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم نولفادكس لعلاج سرطان الثدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يمكن استخدام نولفادكس لعلاج العقم لدى النساء الناتج عن قصور إنتاج البويضات (التبييض) وإطلاقها على نحو&nbsp;مناسب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يمكن أن يقلل نولفادكس من خطر الإصابة بسرطان الثدي الذي يحدث لدى النساء اللاتي لديهن احتمال متزايد للإصابة بسرطان الثدي (خطر إصابتكِ). من المهم أن يقيّم اختصاصي الرعاية الصحية المتابع لكِ مدى خطر إصابتكِ بسرطان الثدي ويناقش النتيجة معكِ قبل بدء تناولكِ للعلاج. هناك عدد من الأدوات المحددة المتاحة لتقييم مدى خطر الإصابة بسرطان الثدي، استنادًا إلى معلومات مثل عمركِ، وتاريخ عائلتكِ الصحي، والعوامل الوراثية، والعوامل الإنجابية (مثل العمر الذي بدأت الدورة الشهرية وتوقفت فيه لديكِ، أو ما إذا كان لديكِ أطفال أم لا، أو ما إذا تلقيتِ أو كنتِ تتلقين علاجًا هرمونيًا بديلاً و/أو حبوب منع الحمل الفموية)، وأي إصابات سابقة لكِ بأمراض الثدي. على الرغم من أن الأدوات يمكن أن تقيّم مدى خطر إصابتكِ بسرطان الثدي، إلا أن هذا لا يعني بالضرورة أنكِ ستُصابين به، فالخطر المتزايد للإصابة بسرطان الثدي يعني أن احتمال إصابتكِ به أكبر. إذا كنتِ أنتِ واختصاصي الرعاية الصحية المتابع لكِ تفكران في أن تستخدمي نولفادكس لهذا الغرض، فمن المهم أن تفهمي الفوائد والآثار الجانبية لتناول نولفادكس لأنكِ لا تعانين حاليًا من سرطان الثدي كما أن نولفادكس يقلل من خطر الإصابة بسرطان الثدي، ولكنه لا يمنعه تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ ترغبين في معرفة المزيد حول كيفية تحديد ما إذا كان تاموكسيفين مناسبًا لكِ أم لا، فهناك المزيد من المعلومات للمرضى متاحة على الموقع الإلكتروني للمعهد الوطني للصحة وجودة الرعاية. اطلبي من طبيبكِ التحدث معكِ حول المعلومات المتاحة للمرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية عمل نولفادكس</strong></p><p dir="RTL">الاستروجين عبارة عن مادة طبيعية تُفرز في جسمكِ ويُعرف بأنه &rdquo;هرمون جنسي&ldquo;. تحتاج بعض سرطانات الثدي إلى هرمون الاستروجين لتنمو ويعمل نولفادكس من خلال منع تأثيرات هرمون الاستروجين<strong>. </strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناولي نولفادكس:</strong></p><ul><li dir="RTL">إذا كنتِ حاملاً أو تعتقدين أنكِ قد تكونين حاملاً (اطلعي على قسم &quot;الحمل&quot; أدناه).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حساسية تجاه تاموكسيفين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><ul><li dir="RTL">إذا كنتِ تتناولين دواء أناستروزول.</li><li dir="RTL">إذا كنتِ تتلقين أي علاج للعقم.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ قد أُصبتِ سابقًا بجلطات في الدم ولم يعرف الطبيب أسبابها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد أُصيب أحد أفراد عائلتكِ بجلطات في الدم مجهولة السبب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبركِ طبيبكِ بأنكِ مصابة بمرض منتشر في العائلة يُزيد من مخاطر تَكوّن جلطات الدم.</p><ul><li dir="RTL">إذا كنتِ تتناولين أدوية تُستخدم للوقاية من الجلطات الدموية مثل الوارفارين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناولي نولفادكس إذا انطبق عليكِ أيٌّ مما سبق. وإذا لم تكني متأكدة، فتحدّثي إلى طبيبكِ أو الصيدلي قبل تناول&nbsp;نولفادكس.</p><p>تحذيرات واحتياطات</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي إلى طبيبكِ أو الصيدلي قبل تناول نولفادكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في عمليات ترميم الثدي المتأخرة (من عدة أسابيع إلى أعوام بعد عملية الثدي الأساسية عند نقل بعض الأنسجة لديكِ لتشكيل ثدي جديد)، قد يُزيد نولفادكس من مخاطر تكوّن جلطات الدم في الأوعية الصغيرة الموجودة في سديلة النسيج، مما قد يؤدي إلى حدوث مضاعفات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام علاج نولفادكس لتقليل خطر الإصابة بسرطان الثدي إلا أنه قد يكون مصحوبًا بآثار جانبية خطيرة مثل حدوث جلطات دموية في أوردة ساقكِ (تجلط الأوردة العميقة)، وجلطات دموية في رئتيكِ (الصمة الرئوية) وسرطان الرحم، والتي يمكن أن تكون كلها مميتة. كما قد تحدث آثار جانبية أخرى أقل خطورة مثل هبّات ساخنة، وإفرازات مهبلية، وعدم انتظام الحيض، وألم بالحوض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعتمد تقييم ما إذا كانت فوائد العلاج تفوق المخاطر على عمركِ، وتاريخكِ الصحي، ومستوى خطر الإصابة بسرطان الثدي لديكِ وعلى تقديركِ الشخصي. قد لا يكون العلاج بنولفادكس لتقليل خطر الإصابة بسرطان الثدي مناسبًا لجميع النساء المعرضات لخطر متزايد. تُعد جميع تقييمات الفوائد والمخاطر المحتملة قبل بدء العلاج مع اختصاصي الرعاية الصحية المتابع لكِ ضرورية. يجب أن تدركي أن نولفادكس يقلل من خطر الإصابة بسرطان الثدي، ولكنه لا يمنعه تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ قد أصبتِ من قبل بالوذمة الوعائية الوراثية فإن نولفادكس قد يتسبب في ظهور أعراض الوذمة الوعائية الوراثية أو تفاقمها. إذا عانيتِ من أعراض مثل تورم الوجه والشفتين واللسان والحلق أو أيًا منها مع صعوبة في البلع أو التنفس، فتواصلي مع طبيب فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>ردود فعل جلدية خطيرة</u></p><p dir="RTL">تم الإبلاغ عن ردود فعل تفاعلات جلدية خطيرة بما في ذلك متلازمة ستيفنز جونسون وتقشر الأنسجة المتموتة البشروية التسممي، عند تلقي نولفادكس. توقفي عن استخدام نولفادكس واطلبي الرعاية الطبية فورًا إذا لاحظتِ أيًا من الأعراض المتعلقة بردود الفعل الجلدية الخطيرة المذكورة في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">هذا الدواء غير مخصص للاستخدام مع الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العمليات</strong></p><p dir="RTL">إذا كنتِ ستخضعين لجراحة مُخطط لها، فينبغي عليكِ إبلاغ طبيبكِ أو الصيدلي حيث قد يرغبان في التفكير في إيقاف علاجكِ لفترة قصيرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى ونولفادكس</strong></p><p dir="RTL">اخبري طبيبكِ أو الصيدلي بما إذا كنتِ تتلقين أو تلقيتِ مؤخرًا أو قد تتلقين أيّة أدوية أخرى. ويعود ذلك إلى أنّ نولفادكس يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى ويمكن لبعض الأدوية أن يكون لها تأثير على نولفادكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، اخبري طبيبك أو الصيدلي بما إذا كنتِ تتلقين أي أدوية أخرى:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">وسائل منع الحمل الفموية</li><li dir="RTL">العلاج بالهرمونات البديلة (HRT)</li><li dir="RTL">مضادات الاكتئاب (مثل باروكستين وفلوكستين).</li><li dir="RTL">بوبروبيون (يسُتخدم كمضاد للاكتئاب أو للمساعدة على الإقلاع عن التدخين).</li><li dir="RTL">كينيدين (على سبيل المثال يُستخدم في علاج اضطراب النظم القلبي).</li><li dir="RTL">سيناكاليت/سيناكالسيت (لعلاج اضطرابات الغدة الجار درقية).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية ترقيق الدم مثل الوارفارين. وتُعرف بأدوية &quot;مضادات التخثر&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين الذي يُستخدم لعلاج السل (TB).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُعرف باسم &quot;مثبطات الأروماتاز&quot; تُستخدم لعلاج سرطان الثدي. وتشمل أناستروزول، وليتروزول، وإكسيمستان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل</strong></p><p dir="RTL">ينبغي على النساء القادرات على الحمل استخدام وسائل منع حمل مناسبة غير هرمونية (على سبيل المثال، وسائل منع الحمل الحاجزة) أثناء تلقي العلاج بدواء نولفادكس ولمدة تسعة أشهر إضافية بعد إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع الطبيعي</strong></p><p dir="RTL">إذا كنتِ حاملاً أو تُرضعين إرضاعًا طبيعيًا، أو تعتقدين أنكِ حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>الحمل </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناولي نولفادكس إذا كنتِ حاملاً. هذا لأنه قد يؤثر على جنينكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنبي الحمل والإرضاع الطبيعي أثناء تناول نولفادكس ولمدة تسعة أشهر بعد إيقاف العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا لأنه يجب عليكِ عدم الحمل عند تناول نولفادكس، يُرجى زيارة طبيبكِ للحصول على المشورة بشأن احتياطات منع الحمل التي يجب عليكِ اتخاذها، حيث قد يتأثر بعضها بدواء نولفادكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجبِ عليكِ زيارة طبيبكِ على الفور إذا كنتِ تعتقدين أنكِ أصبحت حاملاً بعد بدء تناول نولفادكس.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الإرضاع الطبيعي</strong></p><p dir="RTL">تحدثي إلى طبيبكِ قبل تناول نولفادكس إذا كنتِ تُرضعين إرضاعًا طبيعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يؤثر نولفادكس على قدرتكِ على القيادة أو استخدام أي أدوات أو آلات. ومع ذلك فقد أُبلغ عن حدوث تعب عند استخدام نولفادكس، وينبغي توخي الحذر أثناء القيادة أو تشغيل الآلات حينما تستمر مثل هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحتوي أقراص نولفادكس على لاكتوز، وثاني أكسيد التيتانيوم، وصوديوم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي أقراص نولفادكس على لاكتوز وهو أحد أنواع السكر. إذا أخبرك طبيبكِ بأنّكِ لا تتحملين بعض أنواع السكر، فتواصلي مع طبيبكِ قبل تناول هذا المنتج الطبي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي أقراص نولفادكس على ثاني أكسيد التيتانيوم. قد يسبب هذا مشكلة لدى عدد قليل من الأشخاص ممن لديهم حساسية تجاه هذا المكون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل قرص، أي أنه يكاد يكون &quot;خاليًا من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناولي نولفادكس دائمًا وفقًا لتوجيهات الطبيب. استشيري الطبيب المتابع لكِ أو الصيدلي إذا لم تكني متأكدة من طريقة&nbsp;تناوله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب بدء العلاج <em>&nbsp;بنولفادكس</em> ومراقبته تحت إشراف طبيب خبير في طب الأورام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>نولفادكس </em>عقار خَطِر. يجب توخي الحذر عند التعامل مع <em>نولفادكس </em>لتقليل خطر التعرض له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا يتعرض الشخص الذي لا يتناول <em>نولفادكس</em> له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ابتلاع الأقراص كاملة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم كسر الأقراص أو سحقها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج سرطان الثدي </strong></p><p dir="RTL">تبلغ الجرعة الموصى بها لسرطان الثدي 20 ملغ يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العقم </strong></p><p dir="RTL">تعتمد جرعة العقم على فترات الحيض (الدورة الشهرية) لديكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الحيض لديكِ منتظمًا، فإن الجرعة الموصى بها تبلغ قرصًا واحدًا 20 ملغ يوميًا في اليوم الثاني والثالث والرابع والخامس من أيام الحيض لديكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يُجدِ ذلك نفعًا، فقد يقترح طبيبكِ تناول جرعة أكبر من نولفادكس خلال فترة الحيض التالية لديكِ. في هذه الحالة تبلغ الجرعة المعتادة 40 ملغ أو 80 ملغ يوميًا في اليوم الثاني والثالث والرابع والخامس من أيام الحيض لديكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يكن الحيض لديكِ منتظمًا، فيمكنكِ بدء تناول الأقراص في أي يوم من الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تقليل خطر الإصابة بسرطان الثدي</strong></p><p dir="RTL">تبلغ الجرعة الموصى بها لتقليل خطر الإصابة بسرطان الثدي 20 ملغ يوميًا لمدة 5 أعوام.</p><p dir="RTL">سيقيّم اختصاصي الرعاية الصحية المتابع لكِ مدى خطر إصابتكِ بسرطان الثدي وذلك باستخدام معلوماتكِ، وتاريخكِ الطبي، وأي إصابات بسرطان الثدي لأفراد في عائلتكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولتِ جرعة أكثر مما ينبغي من نولفادكس </strong></p><p dir="RTL">إذا تناولتِ جرعة أكثر مما ينبغي من نولفادكس، فتحدّثي على الفور إلى طبيبكِ أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيتِ تناول نولفادكس </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيتِ تناول إحدى الجرعات، فتناوليها بمجرد أن تتذكريها. ومع ذلك، إذا كان وقت الجرعة التالية قد اقترب، فتخطي الجرعة المنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناولي جرعة مضاعفة (جرعتين في الوقت ذاته) لتعويض الجرعة المنسيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديكِ أي أسئلة أخرى حول استخدام هذا الدواء، فتحدثي إلى طبيبكِ أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">قد يُسبِّب هذا الدواء، شأنه شأن جميع الأدوية، آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقفي عن تناول نولفادكس واخبري طبيبكِ على الفور بما إذا لاحظتِ أيًا من الآثار الجانبية التالية &ndash; فقد تحتاجين إلى علاج طبي فوري: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض جلطة دم. وهي تشمل تورم الساق أو ربلة الساق، أو ألم الصدر، أو ضيق التنفس، أو الإحساس المفاجئ بالضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض سكتة دماغية. وهي تشمل الحدوث المفاجئ لما يلي: ضعف أو شلل الذراعين أو الساقين، أو عدم القدرة على تحريك الذراعين أو الساقين، أو صعوبة مفاجئة في التحدث أو المشي أو إمساك الأشياء، أو صعوبة في التفكير. تحدث هذه الأعراض بسبب انخفاض الإمداد بالدم في الدماغ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق مما قد يتسبب في صعوبة البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو القدمين أو الكاحلين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح القراص (يُسمى أيضًا &ldquo;شرى&rdquo; أو &ldquo;ارتكاريا&rdquo;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء غير مرتفعة أو تشبه علامة التصويب أو دائرية على الجذع، غالبًا مصحوبة ببثور مركزية، وتقشر الجلد، وتقرحات بالفم والحلق والأنف والأعضاء التناسلية والعينين. يمكن أن يسبق حالات الطفح الجلدي الخطيرة هذه أعراض تشبه الحمى والإنفلونزا [متلازمة ستيفنز جونسون، تقشُّر الأنسجة المُتموّتة البَشرَوِية التسممي] - نادرًا ما تحدث هذه الآثار الجانبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق، صعوبة في البلع أو التنفس (وذمة وعائية). قد يُسبب نولفادكس أعراض الوذمة الوعائية الوراثية أو يزيدها سوءًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اخبري طبيبكِ على الفور بما إذا لاحظتِ أيًا مما يلي: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف غير معتاد من المهبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حيض غير منتظم، خاصةً إذا كان مصحوبًا بنزف أثقل، حيث قد تكون علامة تحذير لنوع معين من السرطان يصيب بطانة رحمكِ (سرطان بطانة الرحم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفرازات مهبلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الراحة في أسفل البطن (الحوض) مثل الشعور بالألم أو الضغط.</p><p dir="RTL">قد تشير هذه الآثار إلى حدوث تغيرات في بطانة الرحم. أحيانًا تكون هذه الآثار خطرة وقد تشمل السرطان. وقد تحدث خلال العلاج بدواء نولفادكس أو بعد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى: </strong></p><p>&nbsp;</p><p>شائعة جدًا (قد تصيب أكثر من شخص واحد من بين 10 أشخاص) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبَّات ساخنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب شخصًا واحدًا على الأكثر من بين 10 أشخاص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (مشكلة في الدم تعني أن عدد خلايا الدم الحمراء لديكِ قليل جدًا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الرؤية بسبب إعتام عدسة العين أو تغيرات في شبكية عينيكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كميات الدهون في الدم (تظهر من خلال اختبارات الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج الساق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الرحم (بما في ذلك تغيرات في بطانته ووجود زوائد حميدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الأعضاء التناسلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترقق الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبارات الدم لوظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوّن خلايا كبد دهنية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات عصبية (تشمل اضطراب حاسة التذوق وتنميلاً أو وخزًا في الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة بجلطات الدم (بما في ذلك جلطات في الأوعية الصغيرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب شخصًا واحدًا على الأكثر من بين 100 شخص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الدم. قد يجعلكِ هذا تصابين بالكدمات بسهولة أو بحالات عدوى خطيرة أو بالتعب الشديد أو عسر&nbsp;التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الرؤية وصعوبة الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم البنكرياس. قد يسبب هذا ألمًا متوسط الشدة إلى شديد في المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كمية الكالسيوم في دمكِ. قد تشمل العلامات الشعور بالإعياء الشديد، أو المرض الشديد، أو العطش. <strong>اخبري طبيبكِ بما إذا حدث هذا </strong>حيث قد يرغب الطبيب في خضوعكِ لاختبارات دم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين. قد تكون الأعراض مثل الالتهاب الرئوي (مثل الشعور بضيق في التنفس والسعال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تليف الكبد (مشكلات في كبدكِ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تصيب شخصًا واحدًا على الأكثر من كل 1000 شخص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات شديدة في الدم. قد يجعلكِ هذا تصابين بالكدمات بسهولة أو بحالات عدوى خطيرة أو بالتعب الشديد أو عسر التنفس.</p><ul><li dir="RTL">تغيرات في قرنية عينيكِ.</li><li dir="RTL">مشكلات في العصب الذي يربط الشبكية لديكِ بدماغكِ.</li><li dir="RTL">تورم العصب البصري.</li><li dir="RTL">في بعض الأحيان حدثت أمراض أكثر شدة في الكبد ومن بين المرضى من توفى بسببها. تشمل أمراض الكبد هذه التهاب الكبد، وتليف الكبد، وتضرر خلايا الكبد، وانخفاض تكوّن الصفراء، وفشل الكبد. قد تشمل الأعراض شعورًا عامًا بالتعب مصحوبًا أو غير مصحوب بيرقان (اصفرار الجلد والعينين).</li><li dir="RTL">تلف بالأوعية الدموية يتسبب في ظهور نقاط حمراء أو أرجوانية على الجلد.</li><li dir="RTL">اضطراب شديد في الجلد. تشمل الأعراض احمرارًا، وتقرحًا، وتقشيرًا.</li><li dir="RTL">وجود الخلايا التي عادةً ما توجد في بطانة الرحم فقط في مكان آخر من الجسم، وتكيسات المبايض، والسرطان (علامات ذلك مذكورة أعلاه).</li><li dir="RTL">كتلة غير سرطانية في البطانة الداخلية للمهبل (تُسمى السلائل المهبلية).</li><li dir="RTL">في بداية العلاج، قد يحدث تفاقم لأعراض سرطان الثدي لديكِ مثل زيادة الألم وزيادة حجم الأنسجة المصابة (المعروف باسم احتدام الورم) أو أي منهما.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا (قد تصيب شخصًا واحدًا على الأكثر من كل 10000 شخص) </strong></p><ul><li dir="RTL">التهاب بالجلد يتسم بطفح جلدي أو حمامي، غالبًا ما يحدث في المناطق المعرضة للضوء (حالة تُسمى الذئبة الحمامية الجلدية).</li><li dir="RTL">حالة جلدية تتسم ببثور جلدية في المناطق المعرضة للضوء، ويرجع ذلك إلى زيادة إنتاج الكبد لمجموعة خاصة من أصباغ الخلايا (تُسمى البرفيرين).</li><li dir="RTL">معاودة إشعاعية - طفح جلدي يشمل احمرارًا، و/أو تورمًا، و/أو بثورًا (مثل حروق الشمس الشديدة) في الجلد بعد تلقي العلاج الإشعاعي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>نولفادكس</em> عقار خَطِر، ويجب توخي الحذر عند التعامل معه لتقليل خطر التعرض له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تقسيم الأقراص أو كسرها أو سحقها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقلي الدواء وخزّنيه في العبوة الأصلية أو الشريط الأصلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لإعطاء الدواء، استخدمي القفازات واغسلي يديكِ جيدًا قبل تناوله وبعد ذلك. في حال عدم ارتداء قفازات، قومي بإمالة الأقراص وضعيها من العبوة/الشريط مباشرةً في كوب دواء مخصص للاستخدام لمرة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا يتعرض الأشخاص الذين لا يتناولونه له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب توخي الحذر عند التعامل مع الأقراص المكسورة أو المسحوقة. تجنبي تلامس دواء <em>نولفادكس</em> مباشرةً للجلد أو الأغشية المخاطية. إذا حدث مثل هذا التلامس، فاغسلي بشرتكِ جيدًا بالماء والصابون، واشطفي عينيكِ جيدًا بالماء المعقم، أو بالماء العادي إذا لم يتوفر الماء المعقم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتجنب الحوامل التعرض لأقراص<em> نولفادكس</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يستخدم أفراد الأسرة القفازات عند التعامل مع الغسيل أو التنظيف داخل المراحيض أو حولها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغلقي غطاء المرحاض قبل تصريف ما به من ماء وقومي بتصريف الماء مرتين بعد كل استخدام من قِبل المريض، لمدة 48 ساعة بعد تلقي العلاج الكيميائي. استخدمي حمامًا منفصلًا عن أفراد الأسرة، إن أمكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسلي المفروشات مرتين وبشكل منفصل عن الغسيل العائلي الآخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا طلب منكِ طبيبكِ التوقف عن أخذ الدواء أو انتهت صلاحيته، فلا تلقيه في مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعدِ تستخدميها، أو أعيديه إلى الصيدلي والذي سيتخلص منه وفقًا لإرشادات التخلص من المواد الخطرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">لا تحتفظي بالدواء إلا إذا طلب منكِ طبيبكِ ذلك.</p><ul><li dir="RTL">احفظي هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</li><li dir="RTL">لا تستعملي هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العلبة الكرتون. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في هذا الشهر.</li><li dir="RTL">لا يُحفظ في درجة حرارة أعلى من ٣٠&nbsp;درجة مئوية. احفظي أقراصكِ في العبوة الأصلية. احفظي شريط الأقراص بداخل العلبة الكرتون. سيحمي هذا دواءكِ من الضوء والرطوبة.</li><li dir="RTL">لا تتخلصي من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعدِ تستعمليها. ستساعد هذه الإجراءات على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات نولفادكس</strong></p><p dir="RTL">المادة النشطة هي تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل قرص نولفادكس 10 ملغ على سيترات تاموكسيفين وفقًا لدستور الأدوية الأوروبي 15.2 ملغ ما يعادل 10 ملغ تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل قرص نولفادكس دي 20 ملغ على سيترات تاموكسيفين وفقًا لدستور الأدوية الأوروبي 30.4 ملغ ما يعادل 20 ملغ تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى عبارة عن كروس كارميلوز الصوديوم، وجيلاتين، ولاكتوز، وماكروجل، وسترات الماغنسيوم، ونشا الذرة، وميثيل هيدروكسي بروبيل سليولوز، وثاني أكسيد التيتانيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص نولفادكس 10 ملغ عبارة عن أقراص بلون يتراوح من الأبيض إلى الأبيض المائل إلى الصفرة مستديرة وثنائية التحدب ومغلفة، تحتوي على علامات على وجه واحد ومستوية على الوجه الآخر. تأتي هذه الأقراص في عبوات (شرائط أو زجاجات) تحتوي على 30 أو 250 قرصًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص نولفادكس دي 20 ملغ عبارة عن أقراص ثمانية الأضلاع بيضاء ومغلفة. مكتوب على أحد جانبيها نولفادكس&nbsp;دي. تأتي هذه الأقراص في عبوات تحتوي على 30 أو 250 قرصًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">حامل ترخيص التسويق:</p><p dir="RTL">AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA,</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">الشركة المصنعة:</p><p dir="RTL">AstraZeneca UK Ltd, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, المملكة&nbsp;المتحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nolvadex
Nolvadex D

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nolvadex
Tamoxifen Citrate Ph. Eur. 15.2 mg (equivalent to 10 mg tamoxifen).

Nolvadex D
Tamoxifen Citrate Ph. Eur. 30.4 mg (equivalent to 20 mg tamoxifen). 
Excipient with known effect
Lactose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Nolvadex is indicated for:</p><p dir="ltr">1.&nbsp;&nbsp;&nbsp; The treatment of breast cancer.</p><p dir="ltr">2.&nbsp;&nbsp;&nbsp; The treatment of anovulatory infertility.</p><p dir="ltr">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The primary prevention of breast cancer in women at moderate or high risk (see section 5.1).</p><p dir="ltr">Women aged less than 30 years old were excluded from primary prevention trials so the efficacy and safety of tamoxifen treatment in these younger women is unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">1. Breast Cancer</p><p dir="ltr">Adults</p><p dir="ltr">The recommended daily dose of tamoxifen is normally 20&nbsp;mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30-40&nbsp;mg per day is not available, although these doses have been used in some patients with advanced disease.</p><p dir="ltr">Elderly people</p><p dir="ltr">Similar dosing regimens of Nolvadex have been used in the elderly with breast cancer and in some of these patients it has been used as sole therapy.</p><p dir="ltr">2. Anovulatory Infertility</p><p dir="ltr">Before commencing any course of treatment, whether initial or subsequent, the possibility of pregnancy must be excluded. In women who are menstruating regularly, but with anovular cycles, the initial course of treatment consists of 20&nbsp;mg given daily on the second, third, fourth and fifth days of the menstrual cycle. If unsatisfactory basal temperature records or poor pre-ovulatory cervical mucus indicate that this initial course of treatment has been unsuccessful, further courses may be given during subsequent menstrual periods, increasing the dosage to 40&nbsp;mg and then to 80&nbsp;mg daily.</p><p dir="ltr">In women who are not menstruating regularly, the initial course may begin on any day. If no signs of ovulation are demonstrable, then a subsequent course of treatment may start 45 days later, with dosage increased as above. If a patient responds with menstruation, then the next course of treatment is commenced on the second day of the cycle.</p><p dir="ltr"><strong>3. Primary prevention of breast cancer </strong></p><p dir="ltr">Nolvadex treatment for the primary prevention of breast cancer should only be initiated by a medical practitioner experienced in prescribing for this indication, and as part of a shared care pathway arrangement, with appropriate patient identification, management and follow up.</p><p dir="ltr">The recommended dose is 20&nbsp;mg daily for 5&nbsp;years for those women at moderate or high risk. There are insufficient data to support a higher dose or longer period of use.</p><p dir="ltr">Before commencing treatment, an assessment of the potential benefits and risks is essential, including calculating a patient&rsquo;s risk of developing breast cancer according to local guidelines and risk assessment tools. Validated algorithms are available that calculate breast cancer risk based on features such as age, family history, genetic factors, reproductive factors and history of breast disease.</p><p dir="ltr">The use of Nolvadex should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account her risk of breast cancer.</p><p dir="ltr">Paediatric population</p><p dir="ltr">The use of Nolvadex is not recommended in children. The safety and efficacy of Nolvadex in children has not yet been established (see sections&nbsp;5.1 and 5.2).</p><p dir="ltr"><u>Method of administration </u></p><p dir="ltr">For administration by the oral route.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                General contraindications (all indications)
Nolvadex should not be used in the following:
•	Pregnancy. Premenopausal patients must be carefully examined before treatment for all indications to exclude the possibility of pregnancy (see also section 4.6).
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Concurrent anastrozole therapy (see section 4.5).

Treatment for infertility 
Nolvadex should not be used in:
•	Patients with a personal or family history of confirmed idiopathic venous thromboembolic events or a known genetic defect.

Primary prevention of breast cancer 
Nolvadex should not be used in:

•	Women with a history of deep vein thrombosis or pulmonary embolus.
•	Women who require concomitant coumarin-type anticoagulant therapy (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The warnings and precautions for use are different depending on the indication being treated. The specific warnings and precautions for the primary prevention of breast cancer can be found at the end of the section.</p><p dir="ltr">Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer.</p><p dir="ltr">An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogen‑like effect of Nolvadex.</p><p dir="ltr">There are several factors that influence the risk of developing endometrial cancer, with the majority of risk factors affecting oestrogen levels. Therefore, Nolvadex treatment may increase the incidence of endometrial cancer. In addition, other risk factors include obesity, nulliparity, diabetes mellitus, polycystic ovary syndrome and oestrogen-only HRT. There is also the general risk for endometrial cancer with increasing age.</p><p dir="ltr">Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially non-menstrual vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.</p><p dir="ltr">In patients with hereditary angioedema, Nolvadex may induce or exacerbate symptoms of angioedema.</p><p dir="ltr">A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.</p><p dir="ltr">Venous thromboembolism</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 2&ndash;3-fold increase in the risk for VTE has been demonstrated in healthy tamoxifen-treated women (see section&nbsp;4.8).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with <em>breast cancer</em>, prescribers should obtain careful histories with respect to the patient&rsquo;s personal and family history of VTE. If suggestive of a prothrombotic risk, patients should be screened for thrombophilic factors. Patients who test positive should be counselled regarding their thrombotic risk. The decision to use tamoxifen in these patients should be based on the overall risk to the patient. In selected patients, the use of tamoxifen with prophylactic anticoagulation may be justified (cross-reference section&nbsp;4.5)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of VTE is further increased by severe obesity, increasing age and all other risk factors for VTE. The risks and benefits should be carefully considered for <em>all</em> patients before treatment with tamoxifen. In patients with <em>breast cancer</em>, this risk is also increased by concomitant chemotherapy (see section&nbsp;4.5). Long-term anticoagulant prophylaxis may be justified for some patients with <em>breast cancer</em> who have multiple risk factors for VTE.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Surgery and immobility: For patients being treated for <em>infertility</em>, tamoxifen should be stopped at least 6&nbsp;weeks before surgery or long-term immobility (when possible) and re-started only when the patient is fully mobile. For patients with <em>breast cancer</em>, tamoxifen treatment should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupting treatment. All patients should receive appropriate thrombosis prophylactic measures and should include graduated compression stockings for the period of hospitalisation, early ambulation, if possible, and anticoagulant treatment.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If <em>any</em> patient presents with VTE, tamoxifen should be stopped immediately and appropriate anti-thrombosis measures initiated. In patients being treated for <em>infertility</em>, tamoxifen should not be re‑started unless there is a compelling alternative explanation for their thrombotic event. In patients receiving tamoxifen for <em>breast cancer</em>, the decision to re-start tamoxifen should be made with respect to the overall risk for the patient. In selected patients with <em>breast cancer</em>, the continued use of tamoxifen with prophylactic anticoagulation may be justified.&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>All</em> patients should be advised to contact their doctors immediately if they become aware of any symptoms of VTE.</p><p dir="ltr">In delayed microsurgical breast reconstruction Nolvadex may increase the risk of microvascular flap complications.</p><p dir="ltr">In an uncontrolled trial in 28 girls aged 2&ndash;10&nbsp;years with McCune Albright Syndrome (MAS), who received 20&nbsp;mg once a day for up to 12&nbsp;months duration, mean uterine volume increased after 6&nbsp;months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established<em> </em>(see section&nbsp;5.1).</p><p dir="ltr">In the literature it has been shown that CYP2D6 poor metabolisers have a lowered plasma level of endoxifen, one of the most important active metabolites of tamoxifen (see section&nbsp;5.2).</p><p dir="ltr">Concomitant medications that inhibit CYP2D6 may lead to reduced concentrations of the active metabolite endoxifen. Therefore, potent inhibitors of CYP2D6 (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided during tamoxifen treatment (see sections&nbsp;4.5 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Radiation recall has been reported very rarely in patients on Nolvadex who have received prior radiotherapy. The reaction is usually reversible upon temporary cessation of therapy and re-challenge may result in a milder reaction. Treatment with Nolvadex was continued in most cases.</p><p dir="ltr">Nolvadex contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p dir="ltr">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p dir="ltr"><strong>Additional precautions relating to primary reduction of breast cancer risk </strong></p><p dir="ltr">Nolvadex therapy for this indication has uncommonly been associated with serious side effects such as pulmonary embolus and uterine cancer (both endometrial adenocarcinoma and uterine sarcoma). In trials comparing tamoxifen to placebo for reduction of the incidence of breast cancer in women at increased risk of breast cancer, the use of tamoxifen was associated with an increased risk of serious and sometimes fatal adverse events including endometrial cancer (approximately 4&nbsp;cases per 1000&nbsp;women over 5&nbsp;years of use) and thromboembolic events (including deep vein thrombosis and pulmonary embolism). Less serious side effects such as hot flushes, vaginal discharge, menstrual irregularities and gynaecological conditions may also occur. Non-gynaecological conditions such as cataracts were also increased (see section&nbsp;4.8). Whether the benefits of treatment are considered to outweigh the risks depends on the woman&#39;s age, health history, and level of breast cancer risk (see sections&nbsp;4.4, 4.8 and 5.1).</p><p dir="ltr">In the primary prevention studies, due to the limited number of patients with a confirmed BRCA mutation there is uncertainty about the absolute benefit in these patients treated with tamoxifen for primary prevention of breast cancer.</p><p dir="ltr">Benign gynaecological conditions (including endometrial polyps, endometriosis, and ovarian cysts) and gynaecological procedures (including hysteroscopy, dilation and curettage, and hysterectomy) were also found to occur more frequently with tamoxifen use.</p><p dir="ltr">Any women receiving or having previously received Nolvadex for risk reduction should be promptly investigated if any abnormal gynaecological symptoms develop, especially non-menstrual vaginal bleeding.</p><p dir="ltr">The risks of tamoxifen therapy are generally lower in younger women than in older women. In the primary prevention trials, in contrast to women aged 50&nbsp;years or older, women younger than 50&nbsp;years did not have an increased risk of endometrial cancer or pulmonary embolism and the increased risk of deep vein thrombosis was small and restricted to the treatment period.</p><p dir="ltr">When considered for primary reduction of breast cancer risk, Nolvadex is contraindicated in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus (see sections&nbsp;4.3 and 4.5). In women who do not have a history of thromboembolic events, but who are at increased risk of thromboembolic events, the benefits and risks of tamoxifen for the primary reduction of breast cancer risk should be carefully considered. Risk factors for thromboembolic events include smoking, immobility and a family history of venous thrombosis; an additional risk factor, is concomitant oral contraceptive or hormone replacement therapy, which is not recommended in women taking tamoxifen. In women receiving tamoxifen for primary reduction of breast cancer risk, tamoxifen should be stopped approximately 6&nbsp;weeks before undergoing elective surgery to reduce the risk of thromboembolic events. Consideration should also be given to discontinuing tamoxifen during periods of immobility.</p><p dir="ltr">The use of tamoxifen for reduction of breast cancer risk has been associated with reduced bone density in premenopausal women. Whether this may result in an increased risk of fracture is not known. Pre-menopausal women taking tamoxifen for this reason should be advised regarding measures to maintain bone health.</p><p dir="ltr"><u>Toxic epidermal necrolysis</u></p><p dir="ltr">Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with Nolvadex treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, Nolvadex should be withdrawn immediately and an alternative treatment considered (as appropriate). If the patient has developed a serious reaction such as SJS or TEN with the use of Nolvadex, treatment with Nolvadex must not be restarted in this patient at any time.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Exacerbation of hereditary angioedema</u></p><p dir="ltr">In patients with hereditary angioedema, tamoxifen may induce or exacerbate symptoms of angioedema.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">When Nolvadex is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration is initiated for the treatment of breast cancer, careful monitoring of the patient is recommended.</p><p dir="ltr">When Nolvadex is used in combination with cytotoxic agents for the treatment of breast cancer, there is increased risk of thromboembolic events occurring. (See also sections&nbsp;4.4 and 4.8). Because of this increase in risk of VTE, thrombosis prophylaxis should be considered for these patients for the period of concomitant chemotherapy.</p><p dir="ltr">The use of tamoxifen in combination with anastrozole as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone.</p><p dir="ltr">As Nolvadex is metabolised by cytochrome P450 3A4, care is required when co-administering with drugs, such as rifampicin, known to induce this enzyme as tamoxifen levels may be reduced. The clinical relevance of this reduction is unknown.</p><p dir="ltr">Pharmacokinetic interaction with CYP2D6 inhibitors, showing a reduction in plasma level of an active tamoxifen metabolite, 4-hydroxy-N-desmethyltamoxifen (endoxifen), has been reported in the literature.</p><p dir="ltr">Pharmacokinetic interaction with CYP2D6 inhibitors, showing a 65-75% reduction in plasma levels of one of the more active forms of the drug, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine) in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided (see sections&nbsp;4.4 and 5.2).</p><p dir="ltr"><strong>Primary prevention of breast cancer risk</strong></p><p dir="ltr">In women receiving tamoxifen for the primary prevention of breast cancer, the use of coumarin type anticoagulants is contraindicated (see sections&nbsp;4.3 and 4.4).</p><p dir="ltr">There is some evidence that hormone replacement therapy may reduce the effectiveness of tamoxifen, and the concomitant use of tamoxifen and oral hormonal contraceptives is not recommended. Therefore, the use of hormone replacement therapy or oral hormonal contraceptives to manage tamoxifen side effects is not recommended (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Women of childbearing potential</u></p><p dir="ltr">Women should be advised not to become pregnant whilst taking Nolvadex and for nine months following the cessation of therapy and should use barrier or other &nbsp;non-hormonal contraceptive methods if sexually active.&nbsp; Premenopausal patients must be carefully examined before treatment to exclude pregnancy.&nbsp; Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking Nolvadex or within nine months of cessation of therapy.</p><p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">Nolvadex must not be administered during pregnancy.&nbsp; There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken Nolvadex, although no causal relationship has been established.</p><p dir="ltr">Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.</p><p dir="ltr">In rodent models of foetal reproductive tract development, tamoxifen was associated with changes similar to those caused by estradiol, ethinylestradiol, clomiphene and diethylstilboestrol (DES).&nbsp; Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES <em>in utero</em> and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix.&nbsp; Only a small number of pregnant women have been exposed to tamoxifen.&nbsp; Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed <em>in utero</em> to tamoxifen.</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">Limited data suggest that Nolvadex and its active metabolites are excreted and accumulate over time in human milk, therefore the drug is not recommended during breast-feeding. The decision either to discontinue nursing or discontinue Nolvadex should take into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Nolvadex is unlikely to impair the ability of patients to drive or operate machinery. However, fatigue has been reported with the use of Nolvadex and caution should be observed when driving or using machinery while such symptoms persist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">The following definitions apply to the incidence of undesirable effects: Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women patients with operable breast cancer treated for 5&nbsp;years and unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication. The safety findings in the breast cancer prevention trials appeared consistent overall with the established safety profile of tamoxifen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 1&nbsp;&nbsp;&nbsp;&nbsp; Adverse Drug Reactions (ADR) by System Organ Class (SOC) and Frequency.</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>SOC</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uterine fibroids</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Endometrial cancer</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uterine Sarcoma (mostly malignant mixed Mullerian tumours)<strong><sup>a</sup></strong></p><p>Tumour Flare<strong><sup>a</sup></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fluid retention</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypercalcaemia (in patients with bony metastases)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ischaemic cerebrovascular events</p><p>Headache</p><p>Light headedness</p><p>Sensory disturbances (including paraesthesia and dysgeusia)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Optic neuritis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cataracts</p><p>Retinopathy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Visual disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Corneal changes</p><p>Optic neuropathy<strong><sup>a</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Hot flushes</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thromboembolic events (including deep vein thrombosis, microvascular thrombosis and pulmonary embolism)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Interstitial pneumonitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Diarrhoea</p><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Changes in liver enzymes</p><p>Fatty liver</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cirrhosis of the liver</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis</p><p>Cholestasis<sup>a</sup></p><p>Hepatic failure<sup>a</sup></p><p>Hepatocellular injury<strong><sup>a</sup></strong></p><p>Hepatic necrosis<strong><sup>a</sup></strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Skin Rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Steven-Johnsons syndrome<strong><sup>a</sup></strong></p><p>Cutaneous vasculitis<sup>a</sup></p><p>Bullous pemphigoid<strong><sup>a</sup></strong></p><p>Erythema multiforme<strong><sup>a</sup></strong></p><p>Toxic epidermal necrolysis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythematosus<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Exacerbation of hereditary angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leg cramp</p><p>Myalgia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vaginal bleeding</p><p>Vaginal discharge</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus valvae</p><p>Endometrial changes (including hyperplasia and polyps)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Endometriosis<sup>a</sup></p><p>Cystic ovarian swelling<sup>a</sup></p><p>Vaginal polyps</p></td></tr><tr><td style="vertical-align:top"><p>Congenital, familial and genetic disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Porphyria cutanea tarda<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Elevated triglycerides</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and</p><p>procedural complications</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Radiation Recall<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Depression</p></td></tr></tbody></table><p dir="ltr"><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>This adverse drug reaction was <u>not</u> reported in the tamoxifen arm (n= 3094) of the above study; however, it has been reported in other trials or from other sources. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size e.g. 3094).&nbsp; This is calculated as 3/3094 which equates to a frequency category of &lsquo;rare&rsquo;.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The event was not observed in other major clinical studies. The frequency has been calculated using the</p><p dir="ltr">upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of &lsquo;very rare&rsquo;.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects can be classified as either due to the pharmacological action of the drug, e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare, or as more general side effects, e.g. gastrointestinal intolerance, headache, light-headedness and occasionally, fluid retention and alopecia.</p><p dir="ltr">When side effects are severe, it may be possible to control them by a simple reduction of dosage (to not less than 20 mg/day) without loss of control of the disease. If side effects do not respond to this measure, it may be necessary to stop the treatment.</p><p dir="ltr">Skin rashes (including rare reports of erythema multiforme, Stevens‑Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, and bullous pemphigoid) and commonly hypersensitivity reactions including angioedema have been reported.</p><p dir="ltr">Cases of exacerbation of angioedema have been reported in patients with hereditary angioedema receiving Nolvadex.</p><p dir="ltr">Uncommonly, patients with bony metastases have developed hypercalcaemia on initiation of therapy.</p><p dir="ltr">Cases of visual disturbances, including rare reports of corneal changes, and</p><p dir="ltr">common reports of retinopathy have been described in patients receiving Nolvadex</p><p dir="ltr">therapy. Cataracts have been reported commonly in association with the</p><p dir="ltr">administration of Nolvadex.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of optic neuropathy and optic neuritis have been reported in patients</p><p dir="ltr">receiving tamoxifen and, in a small number of cases, blindness has occurred.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sensory disturbances (including paraesthesia and dysgeusia) have been reported commonly in patients receiving Nolvadex.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uterine fibroids, endometriosis and other endometrial changes including</p><p dir="ltr">hyperplasia and polyps have been reported.</p><p dir="ltr">Falls in platelet count, usually to 80,000 to 90,000 per cu mm but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.</p><p dir="ltr">Leucopenia has been observed following the administration of Nolvadex, sometimes in association with anaemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe, and rarely cases of agranulocytosis have been reported.</p><p dir="ltr">There is evidence of ischaemic cerebrovascular events and thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism, occurring commonly during tamoxifen therapy (see sections&nbsp;4.3, 4.4 and 4.5). When Nolvadex is used in combination with cytotoxic agents, there is an increased risk of thromboembolic events occurring.</p><p dir="ltr">Leg cramps and myalgia have been reported commonly in patients receiving Nolvadex.</p><p dir="ltr">Uncommonly, cases of interstitial pneumonitis have been reported.</p><p dir="ltr">Nolvadex has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis and hepatocellular injury (including hepatic necrosis).</p><p dir="ltr">Commonly, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of Nolvadex.</p><p dir="ltr">Depression has been reported with frequency very common in association with the use of Nolvadex.</p><p dir="ltr">Cystic ovarian swellings have rarely been observed in women receiving Nolvadex.</p><p dir="ltr">Vaginal polyps have rarely been observed in women receiving Nolvadex.</p><p dir="ltr">Cutaneous lupus erythematosus has been observed very-rarely in patients receiving Nolvadex.</p><p dir="ltr">Porphyria cutanea tarda has been observed very-rarely in patients receiving Nolvadex.</p><p dir="ltr">Fatigue has been reported very commonly in patients taking Nolvadex.</p><p dir="ltr">Radiation Recall has been observed very rarely in patients receiving Nolvadex.</p><p dir="ltr">Uncommonly incidences of endometrial cancer and rare instances of uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with Nolvadex treatment.</p><p dir="ltr"><strong>Primary prevention of breast cancer risk</strong></p><p dir="ltr">The most common adverse events reported from studies in women at increased risk of breast cancer, and occurring more frequently during treatment with tamoxifen than with placebo, were those associated specifically with the pharmacological action of tamoxifen such as vasomotor symptoms (hot flushes, night sweats), menstrual abnormalities\irregularities, vaginal discharge, and vaginal dryness.</p><p dir="ltr">In the primary prevention trials tamoxifen significantly increased the incidence of endometrial cancer, deep vein thrombosis, and pulmonary embolism compared with placebo, but the absolute increase in risk was small. The risk of developing cataracts was also significantly increased with tamoxifen.</p><p dir="ltr"><em>Women under 50&nbsp;years old</em></p><p dir="ltr">A meta-analysis of risk reduction trials stratified by age showed that while women over 50&nbsp;years old at randomisation had a significantly increased risk of endometrial cancer compared with placebo (RR 3.32, 95% CI 1.95-5.67; p&lt;0.0001), women aged under 50&nbsp;years did not (RR 1.19, 95% CI 0.53-2.65; p=0.6). Similarly, women under 50&nbsp;years did not have a significantly increased risk of pulmonary embolism compared with placebo (RR 1.16, 95% CI 0.55-2.43; p=0.60) and their risk of deep vein thrombosis was only significantly increased during the active treatment phase (RR 2.30, 95% CI 1.23-4.31; p=0,009) but not after treatment had ended.</p><p dir="ltr"><em>Gynaecological conditions and procedures</em></p><p dir="ltr">In placebo controlled trials of the use of tamoxifen for the primary reduction of breast cancer risk, benign gynaecological conditions and procedures were more commonly reported with tamoxifen. The IBIS-1 trial found that in 3573 women taking tamoxifen compared to 3566 women on placebo, the following gynaecological conditions and procedures were more common in women taking tamoxifen: abnormal bleeding (842 v 678, p&lt;00001); endometrial polyps (130 v 65, p&lt;0,0001); ovarian cysts (101 v 42, p&lt;00001); hysteroscopy (228 v 138, P&lt;0,0001); pelvic ultrasound (209 v 132, p&lt;00001); dilation and curettage (178 v 94, p&lt;00001); hysterectomy (154 v 104, p=0002) and oophorectomy (103 v 67, p=0006).</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">On theoretical grounds, an overdosage would be expected to cause enhancement of the pharmacological side effects mentioned above. Observations in animals show that extreme overdosage (100&ndash;200 times recommended daily dose) may produce oestrogenic effects.</p><p dir="ltr">There have been reports in the literature that Nolvadex given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.</p><p dir="ltr">There is no specific antidote to overdosage, and treatment must be symptomatic</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Anti-estrogens. ATC code: L02BA01<strong>.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Nolvadex (tamoxifen) is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10&ndash;20%. Tamoxifen does not adversely affect bone mineral density in postmenopausal women.</p><p dir="ltr">An uncontrolled trial was undertaken in a heterogenous group of 28 girls aged 2 to 10&nbsp;years with McCune Albright Syndrome (MAS), who received 20&nbsp;mg once a day for up to 12&nbsp;months duration. Among the patients who reported vaginal bleeding during the pre-study period, 62% (13 out of 21 patients) reported no bleeding for a 6-month period and 33% (7 out of 21 patients) reported no vaginal bleeding for the duration of the trial. Mean uterine volume increased after 6&nbsp;months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established<em> </em>(see section&nbsp;4.4). There are no long-term safety data in children. In particular, the long-term effects of tamoxifen on growth, puberty and general development have not been studied.</p><p dir="ltr">CYP2D6 polymorphism status may be associated with variability in clinical response to tamoxifen. The poor metaboliser status may be associated with reduced response. The consequences of the findings for the treatment of CYP2D6 poor metabolisers have not been fully elucidated (see sections&nbsp;4.4, 4.5 and 5.2)</p><p dir="ltr"><strong>CYP2D6 genotype</strong></p><p dir="ltr">Available clinical data suggest that patients who are homozygote for non-functional CYP2D6 alleles, may experience reduced effect of tamoxifen in the treatment of breast cancer.</p><p dir="ltr">The available studies have mainly been performed in postmenopausal women (see sections&nbsp;4.4 and 5.2).</p><p dir="ltr"><strong>Primary reduction of breast cancer risk</strong></p><p dir="ltr">Nolvadex reduces, but does not eliminate the risk of breast cancer. In clinical trials, Nolvadex decreased the incidence of oestrogen receptor-positive tumours, but did not alter the incidence of oestrogen receptor-negative tumours. The use of Nolvadex should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account her risk of breast cancer.</p><p dir="ltr">The breast cancer primary risk reduction trials include the International Breast Cancer Intervention Study (IBIS-1), the National Surgical Adjuvant Breast and Bowel Project PI study (NSABP P1), and the Royal Marsden Hospital chemoprevention trial (Royal Marsden). All trials were double-blind placebo controlled randomised trials of oral tamoxifen (20&nbsp;mg per day) for the primary reduction of breast cancer risk in women at increased risk of breast cancer. Women were treated for 5&nbsp;years (IBIS-1and NSABP P1) or 8&nbsp;years (Royal Marsden) and followed for up to 20&nbsp;years.</p><p dir="ltr">The IBIS-1, NSABP PI, and Royal Marsden trials all defined breast cancer risk differently, and recruited women with both moderate or high lifetime risk: IBIS-1 included women with a two-fold relative risk if they were aged 45 to 70&nbsp;years, a four-fold relative risk if they were aged 40 to 44&nbsp;years, or a ten-fold relative risk if they were aged 35 to 39&nbsp;years; NSABP P1 included women aged &ge;60&nbsp;years or aged 35 to 59&nbsp;years with a 5-year predicted risk for breast cancer of at least 1.66% as determined using a modified Gail&#39;s model or a history of Lobular Carcinoma In Situ (LCIS) or atypical hyperplasia; and Royal Marsden included healthy women aged 30 to 70&nbsp;years old with an increased risk of developing breast cancer based on family history.</p><p dir="ltr">All trials excluded women with breast cancer (apart from Lobular Carcinoma In Situ - LCIS), a history of invasive cancer, pregnancy, and current or past deep vein thrombosis or pulmonary embolism. Other relevant exclusion criteria included the current use of oral contraceptives (NSABP P1, Royal Marsden), recent or current hormone replacement therapy (NSABP P1), and current anticoagulant use (IBIS-1).</p><p dir="ltr">The majority of women in all trials were aged 59&nbsp;years or below. NSABP PI included the largest proportion of women aged 60&nbsp;years or over (30%). In NSABP P1, the majority of women were white (96%); race was not reported in the other trials. A substantial proportion of women in all trials were premenopausa1 (46% in IBIS-1 and 65% in Royal Marsden) or younger than 50&nbsp;years old (37% NSABP P1).</p><p dir="ltr">A summary of the key entry criteria for each of the trials are shown in Table 2.</p><p dir="ltr">Table 2&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Summary of Key Criteria Used to Select Patients in Each of the Main Studies</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:621px"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Key Entry Criteria</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IBIS 1</strong></p></td><td style="vertical-align:top"><p>Aged 35-70 years</p><p>No previous invasive cancer (except non-melanoma skin cancer)</p><p>Relative risk of developing breast cancer:</p><ul><li>At least two-fold in women aged 45-70</li><li>At least four- fold in women aged 40-44</li><li>At least ten-fold in women aged 35-39</li></ul><p>Calculated using a specifically designed model based on family history and standard risk factors</p></td></tr><tr><td style="vertical-align:top"><p><strong>NSABP P1</strong></p></td><td style="vertical-align:top"><p>Aged &gt;35 years</p><p>No clinical evidence of breast cancer</p><p>5-year predicted risk &gt;1.66% of developing breast cancer based on the Gail model, or a history of LCIS or atypical hyperplasia based on a multivariable logistic regression model</p></td></tr><tr><td style="vertical-align:top"><p><strong>STAR</strong></p></td><td style="vertical-align:top"><p>Aged &gt;35 years</p><p>5 yr predicted risk of &gt;1.66% of developing breast cancer based on Gail model</p></td></tr><tr><td style="vertical-align:top"><p><strong>Marsden</strong></p></td><td style="vertical-align:top"><p>Aged 30 - 70 years old</p><p>No clinical evidence of breast cancer</p><p>Increased risk of developing breast cancer based on family history.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Efficacy results from the trials are shown in Table 3, which includes results of a meta-analysis of individual participant data from over 28,000 women who were treated with tamoxifen or placebo for the primary reduction of breast cancer risk. The results of the individual trials were generally consistent with the findings in the meta-analysis and the risk reduction effects of tamoxifen lasted for more than 10&nbsp;years after treatment ended.</p><p dir="ltr">Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of Key Efficacy and Safety Results from the Primary Risk Reduction Trials</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:104%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>Efficacy</strong></p></td><td colspan="4"><p><strong>Cuzick meta-analysis<sup>a</sup></strong></p></td><td colspan="4"><p><strong>IBIS-1<sup>b</sup></strong></p></td><td colspan="2"><p><strong>NSABP P1<sup>c</sup></strong></p></td><td colspan="2"><p><strong>Royal Marsden<sup>d</sup></strong></p></td></tr><tr><td colspan="2"><p><strong>Tamox n=14,192</strong></p><p><strong>Events</strong></p></td><td colspan="2"><p><strong>Placebo n=14,214</strong></p><p><strong>Events</strong></p></td><td colspan="2"><p><strong>Tamox n=3579</strong></p><p><strong>Events</strong></p></td><td colspan="2"><p><strong>Placebo n=3575</strong></p><p><strong>Events</strong></p></td><td><p><strong>Tamox n=6597</strong></p><p><strong>Events</strong></p></td><td><p><strong>Placebo n=6610</strong></p><p><strong>Events</strong></p></td><td><p><strong>Tamox n=1238</strong></p><p><strong>Events</strong></p></td><td><p><strong>Placebo n=1233</strong></p><p><strong>Events</strong></p></td></tr><tr><td colspan="4"><p><strong>HR (95% CI)</strong></p></td><td colspan="4"><p><strong>HR (95% CI)</strong></p></td><td colspan="2"><p><strong>RR (95% CI)</strong></p></td><td colspan="2"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>All breast cancer</p></td><td colspan="2"><p>431</p><p>(3.0%)</p></td><td colspan="2"><p>634</p><p>(4.5%)</p></td><td colspan="2"><p>251</p><p>(7.0%)</p></td><td colspan="2"><p>350</p><p>(9.8%)</p></td><td><p>205</p><p>(3.1%)</p></td><td><p>343</p><p>(5.2%)</p></td><td><p>96</p><p>(7.7%)</p></td><td><p>113</p><p>(9.1%)</p></td></tr><tr><td colspan="4"><p>0.67 (0.59-0.76)</p></td><td colspan="4"><p>0.71 (0.60-0.83)</p></td><td colspan="2"><p>NR</p></td><td colspan="2"><p>0.84 (0.64-1.10)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Invasive breast cancer</p></td><td colspan="4" rowspan="2"><p>NR</p></td><td colspan="2"><p>214</p><p>(6.0%)</p></td><td colspan="2"><p>289</p><p>(8.1%)</p></td><td><p>145</p><p>(2.2%)</p></td><td><p>250</p><p>(3.8%)</p></td><td><p>82</p><p>(6.6%)</p></td><td><p>104</p><p>(8.4%)</p></td></tr><tr><td colspan="4"><p>0.73 (0.61-0.87)</p></td><td colspan="2"><p>0.57 (0.46-0.70)</p></td><td colspan="2"><p>0.78 (0.58-1.04)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Non-invasive cancers</p></td><td colspan="2"><p>77</p><p>(0.5%)</p></td><td colspan="2"><p>112</p><p>(0.8%)</p></td><td colspan="2"><p>35</p><p>(1.0%)</p></td><td colspan="2"><p>53</p><p>(1.5%)</p></td><td><p>60</p><p>(0.9%)</p></td><td><p>93</p><p>(1.4%)</p></td><td style="vertical-align:top"><p>14</p><p>(1.1%)</p></td><td style="vertical-align:top"><p>9</p><p>(0.7%)</p></td></tr><tr><td colspan="4"><p>0.72 (0.57-0.92)</p></td><td colspan="4"><p>0.65 (0.43-1.00)</p></td><td colspan="2"><p>0.63 (0.45-0.89)</p></td><td colspan="2"><p>NR</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Oestrogen receptor-positive cancers</p></td><td colspan="2"><p>219</p><p>(1.5%)</p></td><td colspan="2"><p>396</p><p>(2.8%)</p></td><td colspan="2"><p>160</p><p>(4.5%)</p></td><td colspan="2"><p>238</p><p>(6.7%)</p></td><td><p>70</p><p>(1.1%)</p></td><td><p>182</p><p>(2.8%)</p></td><td><p>53</p><p>(4.2%)</p></td><td><p>86</p><p>(7.0%)</p></td></tr><tr><td colspan="4"><p>0.56 (0.47-0.67)</p></td><td colspan="4"><p>0.66 (0.54-0.81)</p></td><td colspan="2"><p>0.38 (0.28-0.50)</p></td><td colspan="2"><p>0.61 (0.43-0.86)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Oestrogen receptor-negative cancers</p></td><td colspan="2"><p>116</p><p>(0.8%)</p></td><td colspan="2"><p>103</p><p>(0.7%)</p></td><td colspan="2"><p>50</p><p>(1.4%)</p></td><td colspan="2"><p>47</p><p>(1.3%)</p></td><td><p>56</p><p>(0.8%)</p></td><td><p>42</p><p>(0.6%)</p></td><td><p>24</p><p>(1.9%)</p></td><td><p>17</p><p>(1.4%)</p></td></tr><tr><td colspan="4"><p>1.13 (0.86-1.49)</p></td><td colspan="4"><p>1.05 (0.71-1.57)</p></td><td colspan="2"><p>1.31 (0.86-2.01)</p></td><td colspan="2"><p>1.4 (0.7-2.6)</p></td></tr><tr><td style="vertical-align:top"><p>All cause mortality</p></td><td style="vertical-align:top"><p>1038 (2.3%*)</p></td><td colspan="3" style="vertical-align:top"><p>1050 (2.5%*)</p></td><td colspan="2" style="vertical-align:top"><p>182 (5.1%)</p></td><td colspan="2" style="vertical-align:top"><p>166 (4.6%)</p></td><td style="vertical-align:top"><p>126 (1.9%)</p></td><td style="vertical-align:top"><p>114 (1.7%)</p></td><td style="vertical-align:top"><p>54 (4.3%)</p></td><td style="vertical-align:top"><p>54 (4.3%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>0&middot;98*</p><p>(0&middot;90&ndash;1&middot;06)</p></td><td colspan="4" style="vertical-align:top"><p>OR 1&middot;10&nbsp;</p><p>(0&middot;88&ndash;1&middot;37)</p></td><td colspan="2" style="vertical-align:top"><p>RR 1.10</p><p>(0.85-1.43)</p></td><td colspan="2" style="vertical-align:top"><p>0.99</p><p>(0.68-1.44)</p></td></tr><tr><td style="vertical-align:top"><p>Breast cancer mortality</p></td><td colspan="2" style="vertical-align:top"><p>30 (0.07%*)</p></td><td colspan="3" style="vertical-align:top"><p>29 (0.07%*)</p></td><td colspan="2" style="vertical-align:top"><p>31 (0.9%)</p></td><td style="vertical-align:top"><p>26</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>12 (0.2%)</p></td><td style="vertical-align:top"><p>11 (0.2%)</p></td><td style="vertical-align:top"><p>12 (1.0%)</p></td><td style="vertical-align:top"><p>9 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>1.03*</p><p>(0.55&ndash;1.92)</p></td><td colspan="3" style="vertical-align:top"><p>OR 1.19</p><p>(0.68&ndash;2.10)</p></td><td colspan="2" style="vertical-align:top"><p>NR</p></td><td colspan="2" style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p><strong>Safety</strong></p></td><td colspan="12"><p><strong>Events</strong></p><p><strong>OR or RR (95% CI)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Endometrial cancer</p></td><td colspan="3"><p>67</p><p>(0.5%)</p></td><td><p>31</p><p>(0.2%)</p></td><td colspan="2"><p>29</p><p>(0.8%)</p></td><td colspan="2"><p>20</p><p>(0.6%)</p></td><td><p>53</p><p>(0.8%)</p></td><td><p>17</p><p>(0.3%)</p></td><td><p>13</p><p>(1.0%)</p></td><td><p>5</p><p>(0.4%)</p></td></tr><tr><td colspan="4"><p>OR 2.18<br />(95%CI 1.39-3.42)</p></td><td colspan="4"><p>OR 1.45<br />(95%CI 0.79-2.71)</p></td><td colspan="2"><p>RR 3.28<br />(95%CI 1.87-6.03)</p></td><td colspan="2"><p>NR</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Other cancers</p></td><td colspan="3"><p>787</p><p>(1.8%)</p></td><td><p>799</p><p>(1.9%)</p></td><td colspan="2"><p>322</p><p>(9.0%)</p></td><td colspan="2"><p>295</p><p>(8.3%)</p></td><td colspan="2" rowspan="2"><p>NR</p></td><td><p>64</p><p>(5.1%)</p></td><td><p>70</p><p>(5.6%)</p></td></tr><tr><td colspan="4"><p>OR 0.98*<br />(95%CI 0.89-1.08)</p></td><td colspan="4"><p>NR</p></td><td colspan="2"><p>NR</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Venousthromboemblism (DVT,PE)</p></td><td colspan="3"><p>131</p><p>(0.9%)</p></td><td><p>82</p><p>(0.6%)</p></td><td colspan="2"><p>104</p><p>(2.9%)</p></td><td colspan="2"><p>62</p><p>(1.7%)</p></td><td><p>DVT 49</p><p>(0.7%)</p><p><br />PE 28</p><p>(0.4%)</p></td><td><p>DVT 34</p><p>(0.5%)</p><p><br />PE 13</p><p>(0.2%)</p></td><td><p>8</p><p>(0.6%)</p></td><td><p>3</p><p>(0.2%)</p></td></tr><tr><td colspan="4"><p>OR 1.60<br />(95%CI 1.21-2.12)</p></td><td colspan="4"><p>OR 1.70<br />(95%CI 1.22-2.37)</p></td><td colspan="2"><p>DVT RR 1.44 (95%CI 0.91-2.30) PE RR 2.15<br />(95%CI 1.08-4.51)</p></td><td colspan="2"><p>NR</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Stroke</p></td><td colspan="4" rowspan="2"><p>NR</p></td><td colspan="2"><p>30</p><p>(0.8%)</p></td><td colspan="2"><p>28</p><p>(0.8%)</p></td><td><p>71</p><p>(1.1%)</p></td><td><p>50</p><p>(0.8%)</p></td><td><p>7</p><p>(0.6%)</p></td><td><p>9</p><p>(0.7%)</p></td></tr><tr><td colspan="4"><p>OR 1.07<br />(95%CI 0.62-1.86)</p></td><td colspan="2"><p>RR 1.42<br />(95%CI 0.97-2.08)</p></td><td colspan="2"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Fractures</p></td><td colspan="3"><p>731</p><p>(5.2%)</p></td><td><p>791</p><p>(5.6%)</p></td><td colspan="2"><p>240</p><p>(6.7%)</p></td><td colspan="2"><p>235</p><p>(6.6%)</p></td><td><p>80</p><p>(1.2%)</p></td><td><p>116</p><p>(1.8%)</p></td><td><p>19</p><p>(1.5%)</p></td><td><p>22</p><p>(1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4"><p>OR 0.92<br />(95%CI 0.83-1.02)</p></td><td colspan="4"><p>RR 1.02**<br />(95%CI 0.86-1.21)</p></td><td colspan="2"><p>RR 0.68<br />(95%CI 0.51-0.92)</p></td><td colspan="2"><p>NR</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Abbreviations: CI = confidence interval, HR = hazard ratio, NS = nonsignificant, NR = not reported, placeb = placebo, RR = risk ratio, tamox = tamoxifen.</p><p dir="ltr"><sup>a</sup> Cuzick 2013 was a meta-analysis of individual participant data from the IBIS-I, NSABP P1, and Royal Marsden primary prevention trials in women at increased risk of breast cancer, and the Italian trial in women at normal risk of breast cancer. The median follow up was 65&nbsp;months.</p><p dir="ltr"><sup>b </sup>Participants were treated with 20&nbsp;mg tamoxifen for 5&nbsp;years; the median follow up was 16&nbsp;years.</p><p dir="ltr"><sup>c </sup>Participants were treated with 20&nbsp;mg tamoxifen for 5&nbsp;years; the median follow up was 6&nbsp;years</p><p dir="ltr"><sup>d </sup>Participants were treated with 20&nbsp;mg tamoxifen for 8&nbsp;years; the median follow up was 13&nbsp;years</p><p dir="ltr">*This result is for all 9 studies included in the meta- analysis not just the tamoxifen studies, as it is not reported for just the tamoxifen studies. There was no heterogeneity between the studies for this category</p><p dir="ltr">** This result is after 8 years median follow up in the IBIS- 1 study, as not all adverse events continued to be recorded after this as no events were anticipated to occur more than 5 years after completion of treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Mortality was a secondary outcome measure for the IBIS-1, NSABP P1 and Royal Marsden trials. In comparing the tamoxifen and placebo arms, no significant difference was found for mortality in each trial. This outcome may be due to confounding factors in these trials such as low event rates, underpowering, close screening leading to early detection of events and subsequent breast cancer treatments.</p><p dir="ltr"><em>Concomitant use of Hormone Replacement Therapy</em></p><p dir="ltr">The IBIS-1 trial found that tamoxifen was effective in reducing the risk of breast cancer in women who were not taking hormone replacement therapy. For women who did use hormone replacement therapy, there was no significant reduction in the risk of developing invasive breast cancers: 110 vs 124 (HR 0.88, 95% CI 0.68-1.13, p=0.31). These findings were consistent over the 20-year study period. In the NSABP P1 trial, women who were taking hormone replacement therapy were excluded from the trial. The Royal Marsden trial was not powered to demonstrate an effect. Therefore, the concomitant use of tamoxifen and hormone replacement therapy is not recommended for primary prevention of breast cancer.</p><p dir="ltr"><em>Effects of age and menopausal status</em></p><p dir="ltr">No age-related effects of tamoxifen on breast cancer incidence were reported in the primary risk reduction trials. Analyses according to age were performed in the final analyses of the IBIS-1 and the NSABP P1 trials. In the IBIS-1 trial, breast cancer incidence was significantly decreased in the tamoxifen vs the placebo group in women aged &le;50 years and &gt;50 years, In the NSABP P1 trial, invasive breast cancer incidence was significantly decreased in the tamoxifen vs the placebo group in women aged &le;49 years, 50 to 59&nbsp;years, and &ge;60&nbsp;years. Thus, no age-related effects of tamoxifen on breast cancer incidence were reported in the trials.</p><p dir="ltr">Analyses according to menopausal status were performed in the 96-month analysis of the IBIS-1 trial. In the IBIS-1 trial, tamoxifen significantly reduced the risk of breast cancer in premenopausal women compared with placebo. It should be noted that the IBIS-1 trial was not sufficiently powered to detect a difference specifically in postmenopausal women. In the NSABP P1 trial, the incidence of invasive breast cancer was significantly lower in the tamoxifen vs placebo group in women aged &ge;60 years, who would have been postmenopausal (40 vs 80, RR 0.49, 95% CI0.33-0.73).</p><p dir="ltr"><em>Lobular carcinoma in situ and atypical hyperplasia</em></p><p dir="ltr">In NSABP P1, there was a 75% breast cancer risk reduction in women with a history of atypical hyperplasia compared with a 37% risk reduction in women with no history of atypical hyperplasia (RR 0.63, 95% CI 0.50-0.78). The risk reductions for women with and without lobular carcinoma <em>in situ</em> were similar.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">After oral administration, tamoxifen is absorbed rapidly with maximum serum concentrations attained within 4&ndash;7 hours.&nbsp; Steady state concentrations (about 300&nbsp;ng/ml) are achieved after four weeks treatment with 40&nbsp;mg daily.&nbsp; The drug is highly protein bound to serum albumin (&gt;99%).&nbsp; Metabolism is by hydroxylation, demethylation and conjugation, giving rise to several metabolites which have a similar pharmacological profile to the parent compound and thus contribute to the therapeutic effect.&nbsp; Excretion occurs primarily via the faeces and an elimination half‑life of approximately seven days has been calculated for the drug itself, whereas that for N-desmethyltamoxifen, the principal circulating metabolite, is 14 days.</p><p dir="ltr">In a clinical study where girls between 2 and 10 years with McCune Albright Syndrome (MAS) received 20 mg tamoxifen once a day for up to 12 months duration, there was an age-dependent decrease in clearance and an increase in exposure (AUC), (with values up to 50% higher in the youngest patients) compared with adults.</p><p dir="ltr">Tamoxifen is metabolised mainly via CYP3A4 to N-desmethyl-tamoxifen, which is further metabolised by CYP2D6 to another active metabolite endoxifen. In patients who lack the enzyme CYP2D6 endoxifen concentrations are approximately 75% lower than in patients with normal CYP2D6 activity. Administration of strong CYP2D6 inhibitors reduces endoxifen circulating levels to a similar extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Tamoxifen was not mutagenic in a range of <em>in vitro</em> and <em>in vivo</em> mutagenicity tests.&nbsp; Tamoxifen was genotoxic in some <em>in vitro</em> and <em>in vivo</em> genotoxicity tests in rodents.&nbsp; Gonadal tumours in mice and liver tumours in rats receiving tamoxifen have been reported in long-term studies.&nbsp; The clinical relevance of these findings has not been established.</p><p dir="ltr">Tamoxifen is a drug on which extensive clinical experience has been obtained.&nbsp; Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Croscarmellose Sodium Ph. Eur.</p><p dir="ltr">Gelatin Ph. Eur.</p><p dir="ltr">Lactose Ph. Eur.</p><p dir="ltr">Macrogol 300 Ph. Eur.</p><p dir="ltr">Magnesium Stearate Ph. Eur.</p><p dir="ltr">Maize Starch Ph. Eur.</p><p dir="ltr">Methylhydroxypropylcellulose Ph. Eur.</p><p dir="ltr">Titanium Dioxide Ph. Eur. (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30&deg;C. Store in the original container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Aluminium blister pack containing 30 or 250 tablets.</p><p dir="ltr">HDPE bottles containing 30 or 250 tablets. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>